


Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Amendments are illustrated by showing deletions by ~~strikethrough~~ or
[[double brackets]] and additions by underlining)

1 (currently amended) : A compound of formula I,



wherein



n1 is 1;

X is, independently for each occurrence, $(CHR^{11})_{n_3}(CH_2)_{n_4}Z(CH_2)_{n_5}$;
Z is O, $N(R^{12})$, S, or a bond;

n3 is, independently for each occurrence, 0 or 1;

n4 and n5 each is, independently for each occurrence,
0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH_2 , CS, or a
bond;



R^2 , R^{11} , and R^{12} each is, independently for each
occurrence, H or an optionally substituted moiety
selected from the group consisting of $(C_{1-6})alkyl$ and

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 3

aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R⁸ or R³⁰; R³ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R³⁰;

R⁴ and R⁵ each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R³⁰, wherein each said substituent is independently selected, or R⁴ and R⁵ can be taken together with the carbons to which they are attached to form aryl;

R⁶ is, independently for each occurrence, H or an ~~optionally substituted moiety selected from the group consisting of~~ (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl (C₁₋₆)alkyl, wherein said ~~optionally substituted moiety is~~ optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, N(R⁸R⁹), COOH, CON(R⁸R⁹), and halo X¹, X², and X³,

where R⁸ and R⁹ each is, independently for each occurrence, H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, or aryl(C₁₋₆)alkyl;

R⁷ is, independently for each occurrence, H, =O, =S, or an ~~optionally substituted moiety selected from the group consisting of~~ (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl,


Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 4

~~(C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl,~~
~~(C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl,~~
~~heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said~~
~~optionally substituted moiety is optionally substituted with~~
~~one or more substituents each independently selected from~~
~~the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, N(R⁸R⁹),~~
~~-COOH, CON(R⁸R⁹), and halo X¹, X², and X³;~~

R¹⁰ is C;

R²¹ is, independently for each occurrence, H or an
optionally substituted moiety selected from the group
consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein
said optionally substituted moiety is optionally
substituted with one or more substituents each
independently selected from the group consisting of R⁸
and R³⁰;

R²² is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R⁸-CO-, or
a substituent according to the formula



R²⁴ and R²⁵ each is, independently for each occurrence,
H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;


R³⁰ is, independently for each occurrence, (C₁₋₆)alkyl,
-O-R⁸, -S(O)_{n6}R⁸, -S(O)_{n7}N(R⁸R⁹), -N(R⁸R⁹), -CN, -NO₂,

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 5


$-\text{CO}_2\text{R}^8$, $-\text{CON}(\text{R}^8\text{R}^9)$, $-\text{NCO}-\text{R}^8$ $-\text{NH}-\text{CO}-\text{R}^8$, or halogen;
n₆ and n₇ each is, independently for each occurrence, 0, 1, or 2;
wherein said heterocyclyl is azepinyl, benzimidazolyl,
benzisoxazolyl, benzofurazanyl, benzopyranyl,
benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl,
benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl,
dihydrobenzothienyl, dihydrobenzothiopyranyl,
dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl,
imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl,
isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl,
isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl,
2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:

either R⁶ is H or R⁷ is =O, -H, or =S wherein when R⁶ is H,




then R¹⁰ and R⁷ are taken together to form ; or when R⁷ is =O, -H, or =S, then R¹⁰ and R⁶ are taken together



Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 6


wherein X^1 , X^2 , and X^3 each is, independently, H, halogen, $-\text{NO}_2$, $-\text{NCO}-\text{R}^8-\text{NH}-\text{CO}-\text{R}^8$, $-\text{CO}_2\text{R}^8$, -CN, or $-\text{CON}(\text{R}^8\text{R}^9)$; and

when R^1 is $\text{N}(\text{R}^{24}\text{R}^{25})$, then n_3 is 1, n_4 and n_5 each is 0, Z is a bond, and R^3 and R^{11} can be taken together to form




wherein n_2 is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl, or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl, or a pharmaceutically acceptable salt thereof.

2 (original): A compound according to claim 1, wherein:



X is $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$ or Z, wherein Z is O, S, or $\text{N}(\text{R}^{12})$; or a pharmaceutically acceptable salt thereof.

3 (withdrawn): A compound according to claim 2, wherein:




X is $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$; and

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 7

n1 is 0;
or a pharmaceutically acceptable salt thereof.

4 (withdrawn) : A compound according to claim 2,
wherein:



R¹ is R²²-S ;


n3, n4, and n5 each is 0;

Z is a bond;

Y is, independently for each occurrence, CO or CS; and
n1 is 0;

or a pharmaceutically acceptable salt thereof.


5 (original) : A compound according to claim 2,
wherein:



R¹ is R²¹ ;

R⁶ is H;

n1 is 1;



R⁷ and R¹⁰ are taken together to form X¹ ;

n3 is 1 and R¹¹ is H;

Z is O or a bond;

n5 is 0; and

Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 8

6 (withdrawn) : A compound according to claim 2,
wherein:

R¹ is N(R²⁴R²⁵);

n1 is 0;


n3 is 1;

n4 is 0;

n5 is 0;


Y is CO or CS;

Z is a bond; and



R³ and R¹¹ are taken together to form (R³)_{n2}
or a pharmaceutically acceptable salt thereof.


7 (original) : A compound according to claim 2,
wherein:



R¹ is ;

R⁷ is H or =O;

n1 is 1;



R⁶ and R¹⁰ are taken together to form (R⁶)_{n2}
n3 is 1 and R¹¹ is H;
n5 is 0;
Y is CO or CH₂; and

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 9

Z is O or a bond;
or a pharmaceutically acceptable salt thereof.

8 (withdrawn) : A compound according to claim 3,
wherein said compound is

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
5-butyl-7-(2-(4-cyanophenylmethyimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 10

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxoethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxoethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or a pharmaceutically acceptable salt thereof.

9 (previously presented) : A compound according to claim 5, wherein said compound is

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 11

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.

10 (previously presented): A compound according to claim 9, wherein said compound is

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.

11 (withdrawn): A compound according to claim 6, wherein said compound is

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;

or a pharmaceutically acceptable salt thereof.

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 12

12 (original): A compound according to claim 7, wherein said compound is

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxoethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

13 (currently amended): A compound according to claim 2 wherein said compound is




1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine;

1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine; or


1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.


14 (previously presented): A compound according to claim 2, wherein said compound is



Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 13



Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 14



or a pharmaceutically acceptable salt thereof.

15 (currently amended): A pharmaceutical composition for use in treating a disease selected from the group consisting the treatment of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer, and or hematopoietic cancer, in a patient in need thereof, comprising an a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein said therapeutically effective amount is an amount that is effective for the treatment of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer, or hematopoietic cancer in said patient.

16 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said





Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 15

disease is selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer and hematopoietic cancer.






17 (canceled)

18 (canceled)

19 (original) : A compound according to claim 2, wherein said compound is




Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 16



; or

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 17



or a pharmaceutically acceptable salt thereof.

20 (currently amended) : A pharmaceutical composition for ~~use in treating a disease selected from the group consisting~~ the treatment of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis and or hepatitis delta virus infection in a patient in need thereof, comprising an a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein said therapeutically effective amount is an amount that is effective for the treatment of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis or hepatitis delta virus infection in said patient.

21 (previously presented) : A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of fibrosis,

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 18

benign prostatic hyperplasia, atherosclerosis, restenosis and hepatitis delta virus infection.